TY - JOUR
T1 - Dengue Vaccines
T2 - An Update
AU - Torres-Flores, Jesús M.
AU - Reyes-Sandoval, Arturo
AU - Salazar, Ma Isabel
N1 - Publisher Copyright:
© 2022, The Author(s).
PY - 2022/5
Y1 - 2022/5
N2 - Dengue is one of the most prevalent mosquito-borne diseases in the world, affecting an estimated 390 million people each year, according to models. For the last two decades, efforts to develop safe and effective vaccines to prevent dengue virus (DENV) infections have faced several challenges, mostly related to the complexity of conducting long-term studies to evaluate vaccine efficacy and safety to rule out the risk of vaccine-induced DHS/DSS, particularly in children. At least seven DENV vaccines have undergone different phases of clinical trials; however, only three of them (Dengvaxia®, TV003, and TAK-003) have showed promising results, and are addressed in detail in this review in terms of their molecular design, efficacy, and immunogenicity. Safety-related challenges during DENV vaccine development are also discussed.
AB - Dengue is one of the most prevalent mosquito-borne diseases in the world, affecting an estimated 390 million people each year, according to models. For the last two decades, efforts to develop safe and effective vaccines to prevent dengue virus (DENV) infections have faced several challenges, mostly related to the complexity of conducting long-term studies to evaluate vaccine efficacy and safety to rule out the risk of vaccine-induced DHS/DSS, particularly in children. At least seven DENV vaccines have undergone different phases of clinical trials; however, only three of them (Dengvaxia®, TV003, and TAK-003) have showed promising results, and are addressed in detail in this review in terms of their molecular design, efficacy, and immunogenicity. Safety-related challenges during DENV vaccine development are also discussed.
UR - http://www.scopus.com/inward/record.url?scp=85130939819&partnerID=8YFLogxK
U2 - 10.1007/s40259-022-00531-z
DO - 10.1007/s40259-022-00531-z
M3 - Artículo
C2 - 35608749
AN - SCOPUS:85130939819
SN - 1173-8804
VL - 36
SP - 325
EP - 336
JO - BioDrugs
JF - BioDrugs
IS - 3
ER -
